While not specifically optimized for detecting exon‐level DMD deletions and duplications, chromosomal microarray (CMA) has the ability to detect many DMD copy number changes, even though it is a broad first‐tier test to assess for copy number changes responsible for developmental disabilities or congenital anomalies (Miller et al., 2010), and is not specifically indicated to evaluate for dystrophinopathies. The gene discussed is DMD; the disease is developmental disability.